Mutational analysis to understand the role of CHML in developmental regression

突变分析以了解 CHML 在发育回归中的作用

• 批准号: 8877784
• 负责人: Eugene Yu
• 金额: $ 23.69万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-06-01 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8877784
• 关键词: Affect; Affinity; Alleles; Alzheimer' s Disease; Amino Acid Sequence; Apoptosis; Autophagocytosis; Behavioral; Biological Process; Biomedical Research; Brain; Candidate Disease Gene; Cell physiology; Cells; Choroid; Choroideremia; Clinical; Clustered Regularly Interspaced Short Palindromic Repeats; Code; Complementary DNA; Complex; Cytokinesis; Development; Disease; Employee Strikes; Engineering; Enrollment; Event; Evolution; Exhibits; Eye; Family; Financial compensation; Foundations; Future; GTP-Binding Proteins; Genes; Genetic; Genome; Genomics; Genotype; Goals; Guanosine Triphosphate Phosphohydrolases; Heterozygote; Histocompatibility Testing; Human; Inherited; Knock-out; Lead; Link; Magnetic Resonance Imaging; Mammals; Mediating; Membrane; Membrane Protein Traffic; Messenger RNA; Missense Mutation; Modeling; Molecular; Motor; Mus; Mutant Strains Mice; Mutation; Nerve Degeneration; Neuraxis; Neurodegenerative Disorders; Nonsense Mutation; Organ; Organism; Orthologous Gene; Parents; Patients; Peptide Sequence Determination; Phenotype; Photoreceptors; Play; Proteins; Rab escort protein; Rare Diseases; Reporting; Reverse Transcription; Role; Siblings; Specificity; Structure; Structure of retinal pigment epithelium; System; Testing; Therapeutic Intervention; Therapeutic Studies; Time; Tissues; United States National Institutes of Health; Zebrafish; autism spectrum disorder; base; body system; brain tissue; cell motility; cilium biogenesis; cognitive function; design; intercellular communication; loss of function; mouse model; mutant; novel; novel therapeutic intervention; null mutation; paralogous gene; prenylation; prevent; programs; public health relevance; response; success; white matter

 DESCRIPTION (provided by applicant): Studies on rare diseases are important because they help to unravel the underlying mechanisms of diseases which may lead to novel therapies for patients. These efforts also offer rare opportunities to discover novel biological processes with major significance in biomedical research. This application is designed to explore a unique genotype-phenotype relationship based on a patient who is enrolled in the NIH Undiagnosed Disease Program (UDP). The patient harbors two compound heterozygous missense mutations in the CHML gene, with one mutant allele inherited from each parent. The patient exhibits developmental regression and neurodegeneration, including progressive cortical and white matter loss. The abnormal phenotypes are absent in the patient's siblings, who do not carry either mutation, and in their parents. In humans and other mammals, the paralogous genes CHM and CHML code for the Rab escort proteins REP-1 and REP-2, respectively. The Rab family consists of a large number of GTPases, which regulate complex membrane trafficking events. Posttranslational prenylation is required for targeting Rabs to specific subcellular membranes. REPs are essential for appropriate prenylation of Rabs. In zebrafish, there is only a single REP-coding gene, chm, and a nonsense mutation of the gene leads to degeneration of multiple organs. Extensive functional studies have been carried out on mammalian CHM orthologs. Null and missense mutations of CHM lead to degeneration of tissues in the eyes of patients with choroideremia. It has been proposed that tissues outside of the eyes in these patients, such as brain tissues, are likely protected by CHML. However, surprisingly, there are almost no functional studies of CHML orthologs despite their perceived importance until the first evidence of the impact of CHML from this UDP case. In this application, we propose to be the first group to test the related major hypothesis that CHML is an indispensable protector of brain tissues from degeneration using mouse mutations of Chml based on its high conservation with the human ortholog. In Aim 1, we will engineer Chml null alleles and the UDP patient-specific missense mutations in mice. In Aim 2, we will analyze the phenotypic consequences of compound heterozygosity of the missense mutations and the null alleles as loss-of-function controls. Phenotypic characterizations will include magnetic resonance imaging (MRI) and stereology analysis of brain structures as well as behavioral analysis of motor and cognitive functions. We will also analyze Rab prenylation in the mutant mice to explore the mechanistic link between genotypes and phenotypes. The success of this project will reveal for the first time the essential role of CHML in maintaining the integrity of the central nervous system, thereby laying the mechanistic foundation for future studies on the UDP patient, including therapeutic studies. The success of this project will also open up possibilities that CHML mutations and CHML-associated biological processes may play critical roles in other neurodegenerative disorders as well as autism spectrum disorder in which developmental regression is an important clinical feature.

 描述(由申请人提供)：对罕见疾病的研究很重要，因为它们有助于揭示疾病的潜在机制，这可能会为患者带来新的治疗方法。这些努力也为发现在生物医学研究中具有重要意义的新的生物过程提供了难得的机会。这项应用旨在探索一种独特的基因型-表型关系，基于一名登记在NIH未诊断疾病计划(UDP)中的患者。患者在CHML基因中有两个复合杂合性错义突变，父母各遗传一个突变等位基因。患者表现为发育退化和神经变性，包括进行性皮质和白质丢失。患者的兄弟姐妹没有携带任何突变，他们的父母也没有异常的表型。在人类和其他哺乳动物中，平行基因CHM和CHML分别编码Rab护送蛋白rep-1和rep-2。RAB家族由大量的GTP酶组成，调节复杂的膜转运事件。翻译后预烯基化是靶向特定亚细胞膜的RAB所必需的。RAP对于RABS的适当预烯基化是必不可少的。在斑马鱼中，只有一个编码rep的基因chm，该基因的无义突变会导致多个器官退化。已对哺乳动物CHM同源基因进行了广泛的功能研究。CHM的零突变和错义突变会导致脉络膜血症患者眼睛组织的退化。有人提出，这些患者的眼睛以外的组织，如脑组织，可能受到CHML的保护。然而，令人惊讶的是，几乎没有关于CHML同源基因的功能研究，尽管它们被认为是重要的，直到第一个证据表明CHML在UDP病例中的影响。在这一应用中，基于CHML与人类同源基因的高度保守性，我们建议成为第一个利用小鼠CHML突变来检验相关主要假设的小组，该假设认为CHML是防止脑组织退化的不可或缺的保护者。在目标1中，我们将在小鼠中设计CHML零等位基因和UDP患者特有的错义突变。在目标2中，我们将分析错义突变和零等位基因作为功能丧失对照的复合杂合性的表型后果。表型特征将包括磁共振成像(MRI)和大脑结构的体视学分析，以及运动和认知功能的行为分析。我们还将分析Rab在突变小鼠中的戊烯基化，以探索基因类型和表型之间的机制联系。该项目的成功将首次揭示CHML在维持中枢神经系统完整性方面的重要作用，从而为未来对UDP患者的研究，包括治疗研究奠定机制基础。该项目的成功还将开启CHML突变和CHML相关生物学过程可能在其他神经退行性疾病以及自闭症谱系障碍中发挥关键作用的可能性，在这些疾病中，发育退化是一个重要的临床特征。